Table 1 Patient characteristics.

From: Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

Characteristic

C-HD

E-HD

P Value

N

148

161

Age (y)

67.4 ± 11.8

64.0 ± 11.9

<0.05

Gender, male (%)

92 (62.2)

85 (52.8)

NS

Dialysis vintage (months)

60 (3, 263)

80 (2, 478)

<0.01

Cause of renal failure (DM, (%))

62 (41.9)

55 (34.2)

NS

Patients with CVD history (%))

36 (24.3)

53 (32.9)

NS

with multiple CVDs (%)

5 (3.4)

10 (6.2)

NS

with cardiac disease (%)

25 (16.9)

31 (19.3)

NS

with apoplexy (%)

11 (7.4)

29 (18.0)

<0.01

with PAD (%)

5 (3.4%)

3 (1.9%)

NS

Body weight (pre HD, kg)

59.3 ± 12.0

58.9 ± 11.2

NS

Body weight (post HD, kg)

57.0 ± 11.7

56.3 ± 10.9

NS

CTR (%)

48.7 ± 6.0

48.7 ± 5.5

NS

Pre-dialysis SBP (mmHg)

154 ± 27

154 ± 25

NS

Pre-dialysis DBP (mmHg)

79 ± 15

80 ± 16

NS

Post-dialysis SBP (mmHg)

142 ± 24

135 ± 24

<0.05

Post-dialysis DBP (mmHg)

75 ± 14

73 ± 14

NS

Patients on Anti-hypertensive agents (%)

108 (73.0)

107 (66.5)

NS

Patients with ESA (%)

124 (83.8)

140 (87.0)

NS

Fatigue Grade

2.9 ± 1.0

2.9 ± 1.1

NS

Pruritis Intensity Grade

3.4 ± 0.9

3.2 ± 0.9

<0.05

Puriritis Frequency Grade

3.2 ± 1.0

3.0 ± 1.1

NS

  1. C-HD, conventional haemodialysis; E-HD, electrolyzed water haemodialysis.
  2. CVD, cardio-cerebrovascular disease; HD, haemodialysis; PAD, peripheral arterial disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoiesis stimulating agents.